Nanoencapsulation of Poorly Soluble Drugs

Click for AAPS poster: "Comparison of In Vivo Efficacy of Nanoencapsulated Paclitaxel with Taxol and Abraxane, AAPS National Meeting, November 11, 2013


Nanoencapsulation of Poorly Soluble Drugs for Intravenous and Oral Delivery

Using its library of patented polymers, ANP has successfully nanoencapsulated poorly soluble drugs to improve their pharmacokinetics, reduce their toxicity, and enhance their therapeutic efficacy.  By enclosing poorly soluble drugs within a capsule of self-assembled polymeric molecules, the resultant amorphous drugs become readily water soluble, thus greatly enhancing their bioavailability.  While protecting the drug from degradation and clearance in the bloodstream and acidic environments, the encapsulating polymers also shield the drug from binding proteins, digesting enzymes, and in vivo precipitation.  Based on our extensive experience with many poorly soluble drugs, we can structurally fine-tune our polymers for maximum efficacy of each insoluble drug’s therapeutic performance.  Our nanoencapsulation technology is ideal for formulating poorly soluble drugs into soluble surfactant- and solvent-free amorphous drug entities for IV injection.

Contact Us

ANP Technologies®, Inc.

824 Interchange Boulevard
Newark, Delaware 19711
Phone:  302.283.1730

Connect With Us!